MDACC Study No:2008-0372 ( NCT No: NCT01036087)
Title:Phase II Study of Panitumumab, Nab-paclitaxel, and Carboplatin for Patients with Primary Inflammatory Breast Cancer (IBC) without HER2 Overexpression
Principal Investigator:Naoto Ueno
Treatment Agent:Abraxane; Carboplatin; Panitumumab
Study Status:Closed
Study Description:The goal of this clinical research study is to learn how effective the
combination of chemotherapy including both panitumumab, Abraxane
(nab-paclitexal), and carboplatin (PNC) and fluorouracil, epirubicin, and
cyclophosphamide (FEC) used before surgery for the treatment of IBC is. The
safety of PNC combination will also be studied.
Hide details for General InformationGeneral Information

Disease Group:Breast
Phase of Study:Phase II
Treatment Agents:Abraxane
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:None.
Supported By:Abraxis Bio
Return Visit:Standard care based on the institutional guideline. Every one to three weeks
patient will visit to receive chemotherapy over 6 to 7 months.Patients will be
off study 4 months after surgery.
Home Care:Standard care based on the institutional guideline.

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Naoto Ueno
Dept:Breast Medical Oncology
For Clinical Trial Enrollment:713-792-8754
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults